GFT 14

Drug Profile

GFT 14

Alternative Names: GFT-14

Latest Information Update: 14 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genfit
  • Class Antihyperlipidaemics
  • Mechanism of Action G protein-coupled receptor agonists; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lipid metabolism disorders

Most Recent Events

  • 12 Feb 2008 Reformulation work is ongoing for Lipid metabolism disorders
  • 05 May 2006 Phase-II clinical trials in Lipid metabolism disorders in France (PO)
  • 05 May 2006 A phase I clinical study has been added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top